Bodal Chemicals Limited (BODALCHEM)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 consolidated revenue 884cr +77% y-y; EBITDA 128cr +197% y-y (margin 14.4%); PAT 81cr +1259% y-y
- H1 FY27 consolidated revenue 1599cr +67% y-y; EBITDA 203cr +114% y-y; PAT 112cr vs 16cr H1 FY26
- Dye intermediates revenue Q2 345cr +88% y-y; utilization at optimum, no immediate expansion
- Benzene downstream utilization improved to ~85% in Q3; revenue run rate 300-400cr range
- TCCA business near breakeven; capacity expansion planned to improve margins
- Expect sustained strong margins in H2 FY27; FY27 revenue target ~3000cr with ~12% EBITDA margin
- Other income includes one-offs: 6cr land sale profit, 8.5cr Gujarat subsidy; Punjab subsidy ~50cr pending
- Capex/inorganic growth planned in 100-200cr range; focus on debt reduction and strong ratios
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 BODALCHEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add BODALCHEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Bodal Chemicals Limited
Important.
The summary above is generated automatically from Bodal Chemicals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.